



10-8-04

PATENT
678503-2001.1

Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : David T. CURIEL et al.
Serial No. : 10/697,535
For : INFECTIVITY-ENHANCED CONDITIONALLY-
REPLICATIVE ADENOVIRUS AND USES THEREOF
Filed : October 30, 2003
Examiner : To Be Assigned
Art Unit : 1632

745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: **EV206804647 US**

Date of Deposit: **OCTOBER 7, 2004**

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Adam Ahmed

(Typed or printed name of person mailing paper or fee)

A. Ahmed

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97(b)(3) AND 1.98

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO Form 1449. In accordance with C.F.R. § 1.98(d), no copy of those documents previously submitted to or cited by the USPTO in predecessor application Serial No.

09/569,789, filed May 12, 2000 (i.e., references AA-DZ) of which this application is a continuation in part, is submitted herewith. Copies of references EA-EH are submitted herewith.

Pursuant to 37 CFR §1.97(b)(3), Applicants request the Examiner to consider this Information Disclosure Statement, and to make of record the documents cited on the accompanying PTO form 1449 and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

It is believed that no fees are required by the instant submission as it is prior to receipt of the first Office Action on the merits. However, if any fees are required, or if any overpayment has been made, please charge Deposit Acct. No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Deborah L. Lu
Thomas J. Kowalski
Reg. No. 32,147
Deborah L. Lu
Reg. No. 50,940
Tel. No. (212) 588-0800
Fax No. (212) 588-0500

Encs. PTO Form 1449
References (8)

Based on Form PTO-1449
(3/90)

ATTY. DOCKET NO.

678503-2001.1

SERIAL NO.

10/697,535

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Curiel et al.

FILING DATE

October 30, 2003

GROUP

1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,801,029	09/1998	McCormick	435	172.3	
	AB	5,846,782	12/1998	Wickham et al.	435	679	
	AC	6,096,718	08/2000	Weitzman et al.	514	44	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AD	WO-96/17053	06/1996	PCT			
	AE	WO-96/34969	11/1996	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AF		Aleman et al., "CAR-binding ablation does not change biodistribution and toxicity of adenovirus vectors," 2001, Gene Therapy 8: 1347-1353
	AG		Aleman, R., et al., "Gene Therapy for Gliomas: Molecular Targets, Adenoviral Vectors, and Oncolytic Adenoviruses," Exp. Cell. Res., 252: 1-12, 1999
	AH		Aleman, R., et al., "Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells," Cancer Gene Therapy, 3(5): 296-301, 1996
	AI		Amalfitano, A., et al., "Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors," Proc Natl Acad Sci USA, 93: 3352-6, 1996
	AJ		Anderson, W.F., "Human Gene Therapy," Nature, 392: p. 25-30, 1998
	AK		Arap, W., et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," Science, 279: 377-80, 1998
	AL		Babiss et al., "Cellular Promoters Incorporated into the Adenovirus Genome," 1987, J. Mol. Biol., Vol. 193: 643-650
	AM		Bangma, C.H., et al., "Free Serum Prostate-Specific Antigen and Screening for Prostate Cancer," JAMA, 275(11): 837-8, 1996
	AN		Bergelson, J.M., et al., "Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5," Science, 275: 1320-3, 1997
	AO		Bischoff, J. R., et al., "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells," Science, 274: 373-376, 1996
	AP		Blackwell, J., et al., "Retargeting to EGFR Enhances Adenovirus Infection Efficiency of Squamous Cell Carcinoma," Arch. Otolaryngol. Head Neck Surg., 125: 856-863, 1999
	AQ		Carbone, F.R., et al., "Cross-presentation: A General Mechanism For CTL Immunity and Tolerance," Immunol. Today, 19(8): 368-73, 1998
	AR		Chartier, C., et al., "Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination in Escherichia coli," J. Virol., 70(7): 4805-10, 1996
	AS		Cook, D.R., et al., "Gene Therapy for B-cell Lymphoma in a SCID Mouse Model using an Immunoglobulin-Regulated Diphtheria Toxin Gene Delivered by a Novel Adenovirus-Polylysine Conjugate," Cancer Biother., 9(2): p. 131-41, 1994
	AT		Curiel, "Strategies to Adapt Adenoviral Vectors for Targeted Delivery," Annals New York Academy of Sciences: 158-171
	AU		Dachs et al., "Targeting gene therapy to cancer: A Review," Oncology Res., Vol. 9: 313-325
	AV		Deng, Y., et al., "MHC Affinity, Peptide Liberation, T Cell Repertoire, and Immunodominance All Contribute to the Paucity of MHC Class I-Restricted Peptides Recognized by Antiviral CTL," J. Immunol., 158: 1507-15, 1997



	AW	Dion, L.D., et al., "E1A RNA transcripts amplify adenovirus-mediated tumor reduction," <i>Gene Therapy</i> , 3: 1021-5, 1996
	AX	Dion, L.D., et al., "Quantitative and in vivo activity of adenoviral-producing cells made by cotransduction of a replication-defective adenovirus and a replication-enabling plasmid," <i>Cancer Gene Therapy</i> , 3(4): 230-7, 1996
	AY	Dmitriev, I., et al., "An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism," <i>J. Virol.</i> , 72(12): 9706-13, 1998
	AZ	Dobner, T., et al., "Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor," <i>Science</i> , 272: 1470-3, 1996
	BA	Eck et al., "Gene-based therapy," Goodman & Gilman's <i>The Pharmacological Basis of Therapeutics</i> -Ninth Edition. McGraw-Hill:77-101
	BB	Eustace, D., et al., "Interleukin-6 (IL-6) Functions as an Autocrine Growth Factor in Cervical Carcinomas in Vitro," <i>Gynecol. Oncol.</i> , 50: 15-19, 1993
	BC	Fallaux, F.J., et al., "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses," <i>Human Gene Therapy</i> , 9: 1909-17, 1998
	BD	Fechner, H., et al., "Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers," <i>Gene Therapy</i> , 6: 1520-1535, 1999
	BE	Ferrin, L.J., "Manipulating and Mapping DNA with RecA-Assisted Restriction Endonuclease (RARE) Cleavage," <i>Genet. Eng.</i> , 17: 21-30, 1995
	BF	Fox, "Investigation of gene therapy begins", 2000, <i>Nature Biotechnology</i> , vol. 18: 143-144
	BG	Freytag, S.O., et al., "A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy," <i>Human Gene Therapy</i> , 9: 1323-1333, 1998
	BH	Fucyo, J., et al., "A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo," <i>Oncogene</i> , 19: 2-12, 2000
	BI	Garver R., Jr., et al., "Strategy for achieving selective killing of carcinomas," <i>Gene Therapy</i> , 1: 46-50, 1994
	BJ	Goldman, C.K., et al., "Targeted Gene Delivery to Kaposi's Sarcoma Cells via the Fibroblast Growth Factor Receptor," <i>Cancer Res.</i> , 57: 1447-51, 1997
	BK	Goldsmith, K.T., et al., "Trans Complementation of an E1A-Deleted Adenovirus with Codelivered E1A Sequences to Make Recombinant Adenoviral Producer Cells," <i>Human Gene Therapy</i> , 5: 1341-8, 1994
	BL	Goldsmith, K.T., et al., "trans E1 Component Requirements for Maximal Replication of E1-Defective Recombinant Adenovirus," <i>Virology</i> , 248: 406-19, 1998
	BM	Gomez-Manzano, C., et al., "Adenovirus-mediated Transfer of the p53 Gene Produces Rapid and Generalized Death of Human Glioma Cells via Apoptosis," <i>Cancer Res.</i> , 56: 694-9, 1996
	BN	Goodrum, F.D., et al., D.A., "p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection," <i>J. Virol.</i> , 72(12): p. 9479-90, 1998
	BO	Gotoh, A., et al., "Development Of Prostate-Specific Antigen Promoter-Based Gene Therapy For Androgen-Independent Human Prostate Cancer," <i>J. Urol.</i> , 160: 220-9, 1998
	BP	Hall, A.R., et al., "p53-dependent cell death/apoptosis is required for a productive adenovirus infection," <i>Nat. Med.</i> , 4(9): 1068-72, 1998
	BQ	Hardy, S., et al., "Construction of Adenovirus Vectors through Cre-lox Recombination," <i>J. Virol.</i> , 71(3): 1842-1849, 1997
	BR	Heise, C., et al., "ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents," <i>Nat. Med.</i> , 3: 639-645, 1997
	BS	Heise, C.C., et al., "Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects," <i>Cancer Gene Therapy</i> , 6: 499-504, 1996
	BT	Hemmi, S., et al., "The Presence of Human Coxsackievirus and Adenovirus Receptor Is Associated with Efficient Adenovirus-Mediated Transgene Expression in Human Melanoma Cell Cultures," <i>Human Gene Therapy</i> , 9: 2363-73, 1998
	BU	Hofmann, C., et al., "Ovine Adenovirus Vectors Overcome Preexisting Humoral Immunity against Human Adenoviruses In Vivo," <i>J. Virol.</i> , 73: 6930-36, 1999
	BV	Kasano, K., et al., "Selective Gene Delivery to Head and Neck Cancer Cells via an Integrin Targeted Adenoviral Vector," <i>Clin. Cancer Res.</i> , 5: 2571-2579, 1999
	BW	Kirn, D., et al., "ONYX-015: Clinical data are encouraging," <i>Nat. Med.</i> , 4(12): 1341-2, 1998

	BX	Kirn, D., et al., "Replicating Viruses as Selective Cancer Therapeutics," <i>Mol. Med. Today</i> , 2(12): 519-27, 1996
	BY	Koivunen, E., et al., "Identification of Receptor Ligands with Phage Display Peptide Libraries," <i>J. Nucl. Med.</i> , 40: 883-888, 1999
	BZ	Kong, B., et al., "IL-6 Antisense-Mediated Growth Inhibition of a Choriocarcinoma Cell Line: An Intracellular Autocrine Growth Mechanism," <i>Gynecol. Oncol.</i> , 63: 78-84, 1996
	CA	Krasnykh, V., et al., "Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob," <i>J. Virol.</i> , 72(3): 1844-52, 1998
	CB	Krasnykh, V., et al., "Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism," <i>J. Virol.</i> , 70: 6839-6846, 1996
	CC	Kremer, E. J., et al., "Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer," <i>J. Virol.</i> , 74: 505-512, 2000
	CD	Laquerre et al., "Recombinant Herpes Simplex Virus Type 1 Engineered for Targeted Binding to Erythropoietin Receptor-Bearing Cells," 1998, <i>Journal of Virology</i> , Vol. 72, No. 12:9683-9697
	CE	Leissner et al., "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism," 2001, <i>Gene Therapy</i> 8: 49-57
	CF	Miller, C.R., et al., "Differential Susceptibility of Primary and Established Human Glioma Cells to Adenovirus Infection: Targeting via the Epidermal Growth Factor Receptor Achieves Fiber Receptor-independent Gene Transfer," <i>Cancer Res.</i> , 58: 5738-48, 1998
	CG	Mittereder, N., et al., "Evaluation of the Concentration and Bioactivity of Adenovirus Vectors for Gene Therapy," <i>J. Virology</i> , 70(11): 7498-509, 1996
	CH	Moolten, F.L., "Drug Sensitivity ("suicide") genes for selective cancer chemotherapy," <i>Cancer Gene Therapy</i> , 1(4): p. 279-87, 1994
	CI	Moran, E., "Interaction of adenoviral proteins with pRB and p53," <i>Faseb J.</i> , 7: 880-5, 1993
	CJ	Murray, E.J., et al., "Sequences and Factors Required for the F9 Embryonal Carcinoma Stem Cell Ela-Like Activity," <i>Mol. Cell Biol.</i> , 11(11): 5534-40, 1991
	CK	Nelson, J.E., et al., "Persistence of Recombinant Adenovirus In Vivo Is Not Dependent on Vector DNA Replication," <i>J. Virol.</i> , 71(11): 8902-7, 1997
	CL	O'Riordan, C., et al., "PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo," <i>Human Gene Therapy</i> , 10: 1349-1358, 1999
	CM	Paillard, F., "The Search For The "Best" Cytokine To Induce Antitumor Immunity," <i>Hum Gene Therapy</i> , 9: 2457-8, 1998
	CN	Pasqualini, R., et al., "αv Integrins as receptors for tumor targeting by circulating ligands," <i>Nat. Biotechnol.</i> , 15: 542-6, 1997
	CO	Peng et al., "Viral vector targeting," 1999, <i>Current Opinion in Biotechnology</i> , 10: 454-457
	CP	Raben, D., et al., "Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene," <i>Gene Therapy</i> , 3: 567-80, 1996
	CQ	Rajotte, Molecular Heterogeneity of the Vascular Endothelium Revealed by in Vivo Phage Display," 1998, <i>J. Clin. Invest.</i> Vol. 102: 430-437
	CR	Rasmussen, et al., "Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat," <i>Pharmacol Ther.</i> , 75(1): 69-75, 1997
	CS	Rodriguez, R., et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells," <i>Cancer Res.</i> , 57(13): 2559-63, 1997
	CT	Roelvink, P. W., et al., "Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing Adenoviridae," <i>Science</i> , 286: 1568-1571, 1999
	CU	Roelvink et al., "The coxsachievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F," <i>J. Virol.</i> , Vol. 72(10): 7909-7915
	CV	Rokhlin, O.W., et al., "Expression of Cellular Adhesion Molecules on Human Prostate Tumor Cell Lines," <i>Prostate</i> , 26: 205-212, 1995
	CW	Roth, J., et al., "Gene Therapy for Cancer: What Have We Done and Where Are We Going?," <i>J. Natl Cancer Inst.</i> , 89(1): 21-39, 1997
	CX	Rothmann, T., et al., "Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells," <i>J. Virol.</i> , 72(12): 9470-8, 1998
	CY	Russell, S.J., "Replicating vectors for cancer therapy: a question of strategy," <i>Semin. Cancer Biol.</i> , 5: 437-43, 1994
	CZ	Sandhu et al., "Human Gene Therapy," <i>Critical Reviews in Biotechnol.</i> , Vol. 17(4): 307-326

	DA	Scaria, A., et al., "Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus polylysine-DNA complexes," <i>Gene Therapy</i> , 2: 295-8, 1995
	DB	Schreiber, H., "Tumor Immunology," <i>Fundamental Immunology</i> , Fourth Edition, W.E. Paul, Editor. 1999, Lippincott-Raven Publishers: Philadelphia. p. 1237-1270
	DC	Schuepbach, J., et al., "Inverse Correlation of Antiviral Antibody Titers and the Remission Length in Patients Treated with Viral Oncolysate: A Possible New Prognostic Sign in Acute Myelogenous Leukemia," <i>Cancer</i> , 48: 1363-7, 1981
	DD	Shi, Q., et al., "Modulation of the Specificity and Activity of a Cellular Promoter in an Adenoviral Vector," <i>Human Gene Therapy</i> , 8: 403-10, 1997
	DE	Shinoura, N., et al., "Highly Augmented Cytopathic Effect of a Fiber-mutant E1B-defective Adenovirus for Gene Therapy of Gliomas," <i>Cancer Res.</i> , 59: 3411-3406, 1999
	DF	Sinkovics, J., et al., "New Developments in the Virus Therapy of Cancer: A Historical Review," <i>Intervirolgy</i> , 36: 193-214, 1993
	DG	Spergel, J., et al., "Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation," <i>Proc Natl Acad Sci USA</i> , 88: 6472-6, 1991
	DH	Stevenson, S., et al., "Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular Receptors via the Fiber Head Domain," <i>J. Virol.</i> , 69: 2850-2857, 1995
	DI	Takenawa, J., et al., "Enhanced Expression of Interleukin-6 in Primary Human Renal Cell Carcinomas," <i>J Natl Cancer Inst.</i> 83(22): 1668-72, 1991
	DJ	Tanaka, T., et al., "Viral Vector-targeted Antiangiogenic Gene Therapy Utilizing an Angiostatin Complementary DNA," <i>Cancer Res.</i> , 58: 3362-9, 1998
	DK	Todo, T., et al., "Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent herpes Simplex Virus," <i>Human Gene Therapy</i> , 10: 2741-2755, 1999
	DL	Urban, J.L., et al., "Stepwise Immunologic Selection of Antigenic Variants During Tumor Growth," <i>J. Immunology</i> , 137(9): 3036-41, 1986
	DM	Vanderkwaak et al., "Adenovirus with RGD-modified fiber demonstrates improved gene transfer into ovarian carcinoma cell lines and ovarian primary tumors," <i>Gynecologic Oncology</i> , Vol. 72(3): 505
	DN	Von Seggern et al., "Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells," <i>J. Virol.</i> , 74: 354-362, 2000
	DO	Wickham, T., et al., "Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins," <i>J. Virol.</i> , 71(11): p. 8221-9, 1997
	DP	Wildner, O., et al., "Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer," <i>Gene Therapy</i> , 6: 57-62, 1999
	DQ	Wildner, O., et al., "Therapy of Colon Cancer with Oncolytic Adenovirus Is Enhanced by the Addition of Herpes Simplex Virus-thymidine kinase," <i>Cancer Res.</i> , 59: 410-413, 1999
	DR	Worgall, S., et al., "Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors Following In Vivo Administration," <i>Human Gene Therapy</i> , 8: 37-44, 1997
	DS	Xia, et al., "Structure of the Receptor Binding Domain of Adenovirus Type 5 Fiber Protein," <i>Curr. Top. Microbiol. Immunol.</i> , 199 (1): 39-46, 1995
	DT	Yang, Y., et al., "Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung," <i>Nat. Med.</i> , 1: 890-893, 1995
	DU	Yeh, P., et al., "M., Advances in adenoviral vectors: from genetic engineering to their biology," <i>FASEB J</i> , 11: 615-23, 1997
	DV	Yoshida, Y., et al., "Generation of Fiber-Mutant Recombinant Adenoviruses for Gene Therapy of Malignant Glioma," <i>Human Gene Therapy</i> , 9: 2503-15, 1998
	DW	Yu, D. C., et al., "Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy", <i>Cancer Res.</i> , 59: 1498-1504, 1999
	DX	Yu, D., et al., "Enhanced c-erbB-2/neu Expression in Human Ovarian Cancer Cells Correlates with More Severe Malignancy that can be Suppressed by E1A", <i>Cancer Res.</i> , 53: 891-8, 1993
	DY	Zhang, J., et al., "Vectors For Cancer Gene Therapy," <i>Cancer Metastasis Rev.</i> , 15: 385-401, 1996
	DZ	Zheng, D. Q., et al., "Prostatic Carcinoma Cell Migration via $\alpha v \beta 3$ Integrin, Is Modulated by a Focal Adhesion Kinase Pathway," <i>Cancer Res.</i> , 59: 1655-1664, 1999
	EA	Adachi Y, et al., "A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging," <i>Cancer Res.</i> 2001 Nov 1;61(21):7882-8

	EB		Forsythe JA, et al., "Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1," Mol Cell Biol. 1996 Sep;16(9):4604-13
	EC		He TC, et al., "A simplified system for generating recombinant adenoviruses," Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
	ED		Ohta Y, et al., "Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer," Clin Cancer Res. 1996 Aug;2(8):1411-6
	EE		Shinoura N, et al., "Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas," Cancer Res. 1999 Jul 15;59(14):3411-6
	EF		Suzuki K, et al., "A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency," Clin Cancer Res. 2001 Jan;7(1):120-6
	EG		Takayama K, et al., "The levels of integrin alpha v beta 5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancer cells," Gene Ther. 1998 Mar;5(3):361-8
	EH		Takayama K, et al., "Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ," Cancer Res. 2000 Apr 15;60(8):2169-77
EXAMINER			DATE CONSIDERED
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			